VOR BIOPHARMA INC (VOR)
US9290331084 - Common Stock
Taking everything into account, VOR scores 2 out of 10 in our fundamental rating. VOR was compared to 572 industry peers in the Biotechnology industry. The financial health of VOR is average, but there are quite some concerns on its profitability. VOR has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
VOR had negative earnings in the past year.
In the past year VOR has reported a negative cash flow from operations.
VOR had negative earnings in each of the past 5 years.
In the past 5 years VOR always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of VOR (-96.96%) is worse than 74.87% of its industry peers.
VOR has a worse Return On Equity (-154.15%) than 65.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -96.96% | ||
| ROE | -154.15% | ||
| ROIC | N/A |
ROA(3y)-39.72%
ROA(5y)-62.55%
ROE(3y)-49.12%
ROE(5y)-83.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VOR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, VOR has more shares outstanding
Compared to 5 years ago, VOR has more shares outstanding
VOR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
VOR has an Altman-Z score of -6.67. This is a bad value and indicates that VOR is not financially healthy and even has some risk of bankruptcy.
VOR's Altman-Z score of -6.67 is on the low side compared to the rest of the industry. VOR is outperformed by 67.96% of its industry peers.
There is no outstanding debt for VOR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.67 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 4.69 indicates that VOR has no problem at all paying its short term obligations.
The Current ratio of VOR (4.69) is comparable to the rest of the industry.
VOR has a Quick Ratio of 4.69. This indicates that VOR is financially healthy and has no problem in meeting its short term obligations.
VOR has a Quick ratio (4.69) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.69 | ||
| Quick Ratio | 4.69 |
3. Growth
3.1 Past
VOR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.70%, which is quite good.
EPS 1Y (TTM)12.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, VOR will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.83% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y10.76%
EPS Next 2Y14.83%
EPS Next 3Y12.59%
EPS Next 5Y11.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VOR. In the last year negative earnings were reported.
Also next year VOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VOR's earnings are expected to grow with 12.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.83%
EPS Next 3Y12.59%
5. Dividend
5.1 Amount
VOR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VOR BIOPHARMA INC
NASDAQ:VOR (1/14/2025, 8:12:08 PM)
Premarket: 1.31 -0.03 (-2.24%)1.34
-0.03 (-2.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners81.05%
Inst Owner Change0%
Ins Owners1.04%
Ins Owner Change95.85%
Market Cap92.02M
Analysts86.67
Price Target13.69 (921.64%)
Short Float %1.82%
Short Ratio1.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.14%
Min EPS beat(2)1.46%
Max EPS beat(2)2.83%
EPS beat(4)3
Avg EPS beat(4)2.47%
Min EPS beat(4)-17.69%
Max EPS beat(4)23.28%
EPS beat(8)4
Avg EPS beat(8)0.84%
EPS beat(12)6
Avg EPS beat(12)1.25%
EPS beat(16)8
Avg EPS beat(16)-297.95%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.39%
PT rev (3m)1.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.96%
EPS NY rev (1m)1.03%
EPS NY rev (3m)-0.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.26 | ||
| P/tB | 1.26 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.65
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-1.45
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS0
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -96.96% | ||
| ROE | -154.15% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-39.72%
ROA(5y)-62.55%
ROE(3y)-49.12%
ROE(5y)-83.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7.48% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.69 | ||
| Quick Ratio | 4.69 | ||
| Altman-Z | -6.67 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)212.34%
Cap/Depr(5y)430.47%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.37%
EPS Next Y10.76%
EPS Next 2Y14.83%
EPS Next 3Y12.59%
EPS Next 5Y11.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.9%
EBIT Next 3Y-2.64%
EBIT Next 5YN/A
FCF growth 1Y-6.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.06%
OCF growth 3YN/A
OCF growth 5YN/A